NasdaqGS:RPRXPharmaceuticals
Royalty Pharma (RPRX) Valuation Check After Strong Q1 Earnings And Rising Investor Interest
Royalty Pharma earnings and buyback catch investors’ attention
Royalty Pharma (RPRX) has drawn fresh investor focus after reporting first quarter 2026 earnings with revenue of US$630.58 million and net income of US$294.69 million, alongside continued progress on its multi year share repurchase program.
See our latest analysis for Royalty Pharma.
The stock has picked up momentum, with a 1 day share price return of 3.0% and a year to date share price return of 37.03%, while the 1 year total...